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In patients with Kaposi’s sarcoma (KS), human herpesvirus 8 (HHV-8) can invariably be detected in KS
tumor tissue and, at a lower frequency, in prostate tissue and peripheral blood B lymphocytes. Whereas the
majority of KS spindle cells are latently infected by HHV-8, linear HHV-8 genomes characteristic for lytic
infection are found predominantly in the peripheral blood cells of KS patients. In this study, we show that
HHV-8 can stably infect B lymphocytes in vitro in the presence of Epstein-Barr virus (EBV). We were able to
generate immortalized HHV-81/EBV1 lymphoblastoid cell lines (LCLs) derived from peripheral blood mono-
nuclear cells (PBMC) of EBV2 and EBV1 donors. In HHV-81/EBV1 LCLs, which have the phenotype of ac-
tivated B lymphocytes (CD191, surface immunoglobulin M, CD231, CD301, CD801), HHV-8 was still present
after more than 25 passages (more than 9 months of culture). Latent viral transcripts and proteins were
present in nonstimulated HHV-81/EBV1 LCLs. After induction by phorbol ester and n-butyrate, HHV-81/
EBV1 LCLs expressed lytic HHV-8 transcripts and proteins. Moreover, HHV-8 could be serially passaged from
HHV-81/EBV1 LCLs to fresh PBMC.
Human herpesvirus 8 (HHV-8) was recently detected in
Kaposi’s sarcoma (KS) (11, 18, 30) and B-cell lymphomas (5,
39, 45), as well as in other malignancies and in healthy indi-
viduals. HHV-8 is a type 2 gammaherpesvirus (genus Rhadi-
novirus) with sequence similarity to Epstein-Barr virus (EBV),
herpesvirus saimiri (HVS), equine herpesvirus 2, murine her-
pesvirus 68, and two recently identified herpesviruses causing
retroperitoneal fibromatosis in macaques (34, 40, 41, 48). Al-
though seroprevalence data indicated that HHV-8 is more
widespread and not restricted to KS, HHV-8 is suspected of
possessing transforming activity similar to EBV and HVS,
which cause tumors in their natural hosts and in experimental
animals (2, 15, 16, 19, 24, 27, 44). In most cell lines established
from KS tissue, HHV-8 is lost during continuous propagation.
Several cell lines derived from primary effusion lymphoma
(PEL) and KS, however, are stably infected by latent HHV-8
and can be induced to undergo lytic viral replication and virus
production (6, 38, 42). Serial propagation of HHV-8 on pri-
mary cells or cultured cell lines has not been possible thus far.
In vitro, HHV-8 could be transferred to several cell lines and
primary cells including 293 (13, 37) and B lymphocytes (25);
however, this did not result in stable virus infection. In vivo,
HHV-8 was detected in biopsy specimens of KS lesions (11, 18,
30) but also in prostate tissue (28), semen (28), saliva (47),
peripheral blood B lymphocytes (1, 10), and lymphoid tissue
(4) of KS patients. Human B lymphocytes can also be infected
by EBV, the nearest relative of HHV-8 that is pathogenic to
humans. EBV is able to transform B cells in vitro to permanent
lymphoblastoid cell lines (LCLs) (20). EBV-induced B-cell
transformation leads to a sequential expression of at least 11
latent EBV genes (EBNAs, LMPs, and EBERs), entry into the
cell cycle and continuous cell proliferation, RNA synthesis,
and expression of activation (e.g., transferrin receptor, major
histocompatibility complex class II, CD21, CD23, CD39, CD40
and CD44) and adhesion (e.g., ICAM1, LFA1, and LFA3)
molecules, resulting in a phenotype similar to stimulated B
cells. Thus far, there has been no experimental evidence that
infectious HHV-8 particles can stably infect and transform
either primary cells or cell lines in vitro. In this study, we
present evidence that HHV-8 persistently infects peripheral
blood B lymphocytes and that LCLs continuously infected with
HHV-8 can be established.
MATERIALS AND METHODS
Blood donors. Peripheral blood mononuclear cells (PBMC) were isolated from
EDTA-treated blood of four EBV-negative and EBV-positive healthy individu-
als by Ficoll-Hypaque discontinuous gradient centrifugation (Lymphoflot; Bio-
test AG, Dreieich, Germany) as specified by the manufacturer. Blood donors
were not from HHV-8 risk groups. EBV serologic testing was performed with the
following commercial kits detecting virus capsid antigen (VCA) immunoglobulin
G (IgG) (Fresenius, Bad Homburg, Germany) and IgM (Viramed, Martinsried,
Germany) and Epstein-Barr virus nuclear antigen (EBNA) IgG antibodies (Bio-
test, Dreieich, Germany). EBV-positive individuals were positive for VCA IgG
and EBNA IgG antibodies but negative for VCA IgM antibodies. EBV-negative
individuals were negative for VCA IgG, VCA IgM, and EBNA IgG.
Cell culture and EBV and/or HHV-8 infection. BCBL-1 (38), BC-1 (35), B95-8
(CRL1612), Raji (CCL 86), and LCLs were cultured in RPMI (Life Technolo-
gies, Paisley, Scotland) supplemented with 20% heat-inactivated fetal calf serum
(FCS; Life Technologies), 100 IU of penicillin (Life Technologies) per ml, 100
mg of streptomycin (Life Technologies) per ml, 2 mM L-glutamine (Life Tech-
nologies), and 0.05 mM 2-mercaptoethanol (Sigma, St. Louis, Mo.). For cells at
low density, the 2-mercaptoethanol was replaced by 20 mM bathocuproine di-
sulfonic acid (Sigma), 50 mm a-thioglycerol (Sigma), and 1 mM sodium pyruvate
(Life Technologies). To induce the expression of lytic viral proteins, cells were
treated with 20 ng of phorbol 12-myristate 13-acetate (TPA; Sigma) per ml and
3 mM sodium n-butyrate (Sigma) for 24 h.
Supernatants of either BCBL-1, BC-1, B95-8, or Raji cells grown at very high
densities (5 3 105 per ml) were used to infect PBMC. Supernatants were filtered
through 0.4-mm filters and serially diluted with cell culture medium in 96-well
plates, and PBMC were added to 104 cells per well. For serial virus passage,
supernatants of ABEH-1, ABE-1, GMEH-1, and GME-1 cells were generated
similarly and added to 104 PBMC from an EBV1 donor.
Isolation of cellular DNA and detection of viral DNA by PCR. Total cellular
DNA was prepared from 106 cells by the method of Miller et al. (26). The primer
used to amplify HHV-8 DNA flanked the K12 open reading frame (K12for, 59
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cggaattcatggatagaggcttaacg 39; K12rev, 59 cgctcgagtcagtgcgcgcccgttgc 39). The
length of the expected amplified product is 196 bp. The primers used to amplify
EBV DNA from the BALF5 open reading frame were Epolfor (59 aggttggcggg
gctcagggc 39) and Epolrev (59 agcacaggctagccggcctg 39), and the amplified prod-
uct was 343 bp in size. Each reaction mixture contained 500 ng of cellular DNA,
100 ng of each primer, and 5 U of Taq polymerase (Perkin-Elmer Cetus, Branch-
burg, N.J.). The mixture was cycled in a DNA thermal cycler 2400 (Perkin-
Elmer) for 30 cycles of amplification (96°C for 1 min; 60°C for 1 min; 72°C for
1 min). One-tenth of the PCR products were analyzed on 2% agarose–40 mM
Tris acetate–1 mM EDTA and visualized after ethidium bromide staining. As
negative and positive PCR controls, water and plasmid DNAs of EBV polymer-
ase and K12 cloned into pBluescript KS II1 were used, respectively.
Preparation of RNA and RT-PCR. RNA was extracted from 106 cells with Tri
Reagent (Molecular Research Center, Cincinnati, Ohio) as specified by the
manufacturer. A 5-mg portion of total RNA in 10 ml of water and 1 mg of
oligo(dT)18 primer were heated to 70°C for 10 min and then cooled to 4°C on ice.
A 10-ml volume of reaction mixture (100 mM Tris-HCl [pH 8.3], 6 mM MgCl2,
150 mM KCl, 1 mM each deoxynucleoside triphosphate (Boehringer, Mannheim,
Germany), 30 U of RNase inhibitor [MBI Fermentas, Vilnius, Lithuania], 200 U
of Superscript [Life Technologies]) was added, and the mixture was incubated at
37°C for 1.5 h and heated to 67°C for 15 min. A 2-ml volume of the reverse
transcription reaction mixture was amplified with gene-specific primers in a
100-ml PCR mixture containing 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 0.2
mM each deoxynucleoside triphosphate, 100 ng of each primer, and 5 U of Taq
polymerase. The mixture was cycled in a DNA thermal cycler 2400 for 30 cycles
of amplification (96°C for 1 min; 60°C for 1 min; 72°C for 1 min). One-tenth of
the PCR mixtures were analyzed on 1 or 2% agarose–40 mM Tris-acetate–1 mM
EDTA and visualized after ethidium bromide staining.
The oligonucleotide primers used in this study were K12for, K12rev, VP23for (59
cgcgggtctagaatcgcactcgacaagagtata 39), VP23rev (59 cgcggggaattctttagcgtggggaatacc
aacagga 39), Actfor (59 cgcgaatccccccagtgtgacatgg 39), and Actrev (59 cgcggatccc
agccaggtccagacg 39). As negative controls for these experiments, reverse tran-
scription-PCR (RT-PCR) was performed with 1 mg of total RNA. As negative and
positive PCR controls, water and plasmid DNAs of full-length cDNA of VP23,
actin, and K12 cloned into pBluescript KS II1 were used, respectively.
Flow cytometry. To analyze the surface phenotype of LCLs, BC-1 and BCBL-1
cells (5 3 105) were washed in phosphate-balanced saline (PBS) and FACS buff-
er (PBS containing 2.5% FCS and 0.02% sodium azide) and stained directly with
anti-CD3-phycoerythrin (PE), anti-CD14-PE, anti-CD16-PE, anti-CD19-PE, an-
ti-CD56-PE (Pharmingen, Hamburg, Germany), anti-IgG-fluorescein isothiocy-
nate (FITC), and anti-IgM-FITC (Sigma). Isotype controls were included in each
assay. For indirect staining, cells were incubated first with mouse anti-CD19,
anti-CD20, anti-CD23, or anti-CD30 (Dako Diagnostika, Hamburg, Germany)
and then with goat anti-mouse IgG-FITC (Dianova, Hamburg, Germany). As the
negative control, only goat anti-mouse IgG-FITC was used in each assay. The
cells were washed three times and analyzed on a FACScan with Cellquest soft-
ware (Becton Dickinson, San Jose, Calif.).
Immunofluorescence and confocal microscopy. After stimulation for 24 h with
TPA and n-butryate as described above, the cells were dried on poly-L-lysine-
coated coverslips (Marienfeld, Bad Mergentheim, Germany), fixed with acetone,
and blocked for 1 h with 5% FCS in PBS. After incubation for 1 h with mono-
clonal antibody (MAb) vp4G2 (anti-HHV-8 VP23), kap5C4 (anti-HHV-8 K12),
or 817 (anti-EBV VCA) (Chemicon, Temecula, Calif.) diluted in 5% FCS in
PBS, the cells were incubated for 2 h with Cy3-conjugated goat anti-rat IgG or
goat anti-mouse IgG (Sigma) diluted 1:200 in 5% FCS in PBS. MAbs vp4G2
(23a) and kap5C4 (21a) were generated as described elsewhere. The cells were
washed and examined under a TNT confocal microscope DMIRB (Leica, Ben-
sheim, Germany).
RESULTS
Immortalization of PBMC and persistent viral infection by
EBV and HHV-8. Supernatants of BCBL-1 (HHV-81 PEL cell
line), BC-1 (HHV-81 EBV1 PEL cell line), B95-8 (EBV1
marmoset cell line), and Raji (human EBV-transformed cell
line with a deletion in the EBV genome resulting in an inability
to release virus) cells were used to infect PBMC from four
EBV2 and four EBV1 individuals. Incubation of PBMC with
control supernatant or supernatant of Raji cells did not result
in the outgrowth of LCLs, independent of EBV status, indi-
cating that the EBV present in PBMC from EBV1 individuals
was not sufficient to transform B cells under the conditions
used (Table 1). Incubation with supernatants of B95-8 resulted
in the outgrowth of LCLs in PBMC of each individual, again
independent of EBV status. Supernatants of HHV-81 BCBL-1
cells resulted in the outgrowth of LCLs if PBMC were derived
from EBV1 but not from EBV2 individuals. Interestingly,
supernatants of HHV-81 and EBV1 BC-1 cells resulted in the
immortalization of PBMC from both EBV2 and EBV1 indi-
viduals. Since supernatants from BCBL-1 cells (HHV-81
EBV2) immortalized PBMC from EBV1 but not EBV2 do-
nors, we hypothesized that HHV-8 either provides a cofactor
promoting the immortalization of EBV-transformed B cells or
itself has transforming activity if EBV or EBV-derived cofac-
tors are present. Since supernatants of BCBL-1 cells did not
promote the immortalization of B lymphocytes derived from
EBV2 donors in the assay system we used, we thus far have
no hints for the latter.
Initially, six cell lines were established from PBMC of each
donor and supernatant. PBMC from one donor were used
twice, with a similar outcome. Thus, a total of 54 cell lines were
established by using either BCBL-1 or BC-1 supernatant.
HHV-81 EBV1 LCLs were tested after various passages for
the presence of EBV and HHV-8 DNA by PCR (Fig. 1). Both
EBV and HHV-8 were present in all cell lines derived from
PBMC of EBV1 donors infected with supernatant of the
HHV-81 cell lines BC-1 and BCBL-1, as well as in cell lines
derived from EBV2 donors infected with supernatant of BC-1
cells. In the experiment in Fig. 1, two LCLs, ABEH-1 and
GMEH-1, were tested after 3, 6, 9, 12, 15, 18, and 21 passages
FIG. 1. Persistent infection of LCLs by HHV-8 and EBV. Viral DNAs in the
LCLs ABEH-1 and GMEH-1 were detected by PCR from passages 3 to 21 by
using either EBV (BALF5, 343 bp)- or HHV-8 (K12, 196 bp)-specific primers.
Cellular DNA was extracted after the indicated number of passages, and 500 ng
of each DNA preparation was used in an unnested PCR of 30 cycles. One-tenth
of the PCR mixture was applied to a 2% agarose gel and visualized after
ethidium bromide staining.
TABLE 1. Establishment of HHV-81 EBV1 LCLs from
PBMC of EBV2 and EBV1 donors
Supernatant
LCL outgrowtha after incubation of PBMC from:
EBV1 donor: EBV2 donor:
A B C D E F G I
Control medium —b — — — — — — —
Raji — — — — — — — —
B95-8 14 17 15 15.7 26 19 22.5 24.6
BCBL-1 0.3 1.5 0.3 0.75 Lc L L L
BC-1 1.2 4.3 10 4.8 12 9.6 10.4 13.2
a Outgrowth is expressed as 103 outgrowing LCLs at the highest dilution.
b —, no growth.
c L, initial limited growth.
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and found to be positive for both EBV and HHV-8 with no
apparent decline in viral load. Four immortalized HHV-81
EBV1 cell lines are continuously kept in culture for currently
more than 25 passages and longer than 9 months. The other
HHV-81 EBV1 cell lines were frozen in liquid nitrogen since
they appeared to be similar. Once the HHV-81 EBV1 cell
lines were established, there was no difference in terms of the
efficiency of long-term culture in comparison to EBV1 LCLs.
FIG. 2. Expression of the B-cell antigen CD19 on HHV-81 EBV1 LCLs. HHV-81 EBV1 LCLs (ABEH-1 and GMEH-1), EBV1 HHV-82 LCLs (ABE-1 and
GME-1), BC-1, and BCBL-1 were stained with anti-CD3, anti-CD14, anti-CD16, and anti-CD19 MAbs. Isotype controls were included in each assay. Flow cytometry
was performed by gating on 10,000 living cells.
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All four cell lines kept in continuous cell culture for more than
9 months were found to be positive for both EBV and HHV-8.
Furthermore, none of the HHV-81 EBV1 LCLs have become
negative for either HHV-8 or EBV thus far.
Phenotypic analysis of EBV1 HHV-81 LCLs. Next, we deter-
mined the phenotype of the immortalized cell lines. All HHV-
81 EBV1 LCLs tested were positive for CD19 (B-lymphocyte
antigen) but negative for CD3 (T-lymphocyte marker), CD14
(monocytes/macrophages), and CD16 (NK cells) (Fig. 2), in-
dicating that these cells are of B-lymphocyte origin. Moreover,
HHV-81 EBV1 LCLs expressed surface IgM, as well as B-cell
activation markers CD23, CD30, and CD80 similarly to EBV-
transformed LCLs (Table 2). Surface IgG, CD20, and CD56
were not found on these cells. The phenotype differed from
BCBL-1 and BC-1 cell lines by some markers; e.g., BCBL-1
cells were negative for CD80, and BC-1 cells were negative for
CD30. Intriguingly, the surface phenotype as well as growth
characteristics varied between LCLs from different donors.
Whereas most of the HHV-81 EBV1 LCLs grow in large
conglomerates in suspension similar to EBV-transformed
LCLs, cells of the HHV-81 EBV1 LCL COEH-1 show semi-
adherent growth and are spindle shaped (data not shown).
Latent infection of transformed B-cell lines by HHV-8. We
next tested HHV-81 EBV1 LCLs for expression of the latent
viral transcript T0.7, which codes for kaposin. T0.7 was detect-
ed in the noninduced HHV-81 EBV1 LCL GMEH-1 after
5, 10, and 15 passages by RT-PCR, and expression could be
increased by induction with phorbol ester and n-butyrate (Fig.
3). The signal resulting from the amplification of actin mRNA
was similar for all samples tested, indicating that the RNA
content was comparable. The RT-PCR result was confirmed by
Northern blot analysis, which revealed the presence of T0.7 in
unstimulated ABEH-1 and GMEH-1 cells after more than 25
passages. In accordance with the RT-PCR results, kaposin
protein was detected in the noninduced HHV-81 EBV1
LCLs GMEH-1 and ABEH-1 by immunofluorescence with the
MAb kap5C4 (Fig. 4). Kaposin was also detected on BCBL-1
cells but not on B95-8 cells.
Induction of lytic viral proteins in HHV-81 EBV1 LCLs. We
next investigated whether latent HHV-8 can be reactivated in
HHV-81 EBV1 LCLs. GMEH-1 and ABEH-1 LCLs after 5,
10, and 15 culture passages were stimulated with phorbol ester
and n-butyrate and subsequently tested for lytic viral tran-
scripts coding for VP23 by RT-PCR (Fig. 3). In all immortal-
ized HHV-81 EBV1 LCLs tested, lytic HHV-8 mRNA was
detected after induction by phorbol ester and n-butyrate, sim-
ilar to BC-1 and BCBL-1 cells. In accordance with the RT-
PCR results, the viral capsid protein VP23 was detected by im-
munofluorescence with the MAb vp4G2 in cells of the
HHV-81 EBV1 LCL ABEH-1 and in BCBL-1 cells. No reac-
tivity was seen with B95-8 (Fig. 4) and EBV1 LCLs of the same
donors (data not shown), indicating that there was no cross-
reactivity with EBV proteins. Reactivity against EBV VCA was
detected in B95-1 and in ABEH-1 cells but not in BCBL-1
cells.
Serial passage of HHV-8 from HHV-81 EBV1 LCLs. Since
lytic HHV-8 genes could be induced in HHV-81 EBV1 LCLs,
we hypothesized that HHV-81 EBV1 LCLs are able to pro-
duce infectious viral particles and infect new cells. PBMC of an
EBV1 donor were incubated with supernatants of HHV-81
EBV1 and EBV1 LCLs (Table 3). As anticipated, superna-
tants of the EBV1 LCLs ABE-1 and GME-1 immortalized B
cells. Intriguingly, incubation with supernatants of HHV-81
EBV1 LCLs also promoted the outgrowth of cell lines, where-
as control supernatant of Raji cells or culture medium had no
such effect. Six second-generation cell lines were established
for each supernatant, and one second-generation cell line of
each supernatant was tested by immunofluorescence analysis
after two passages. Cell lines that were derived from PBMC
incubated with supernatant of ABE-1 and GME-1 cells were
found to be positive for EBV VCA and negative for HHV-8
kaposin. Cell lines that were derived from PBMC incubated
with supernatant of cells of the HHV-81 EBV1 LCLs
ABEH-1 and GMEH-1 were positive for both HHV-8 kaposin
and EBV VCA, indicating that HHV-8 has been transferred to
these cells.
DISCUSSION
In this study, we were able to show that (i) peripheral blood
B lymphocytes can be persistently infected by HHV-8 in vitro,
(ii) HHV-8 supports transforming activity of EBV on B cells,
and (iii) infection leads to the outgrowth of permanent HHV-
81 EBV1 LCLs. Infection of PBMC with EBV in vitro results
in the immortalization of B cells and the generation of EBV1
LCLs. In vivo, EBV infection causes a primary infection known
as mononucleosis followed by a lifelong persistence of EBV in
a latent state in B lymphocytes. The frequency of EBV-in-
fected B cells in the peripheral blood was reported to be be-
FIG. 3. Detection of latent HHV-8 transcripts in noninduced, and lytic
HHV-8 transcripts in induced, HHV-81 EBV1 LCLs. RT-PCR analysis of
EBV1 HHV-81 LCL GMEH-1 was performed after 5, 10, and 15 passages
either with or without induction by TPA and sodium butyrate. The RT reaction
was performed by oligo(dT) priming followed by PCR with gene-specific primers
for the latent T0.7 transcript (196 bp), the lytic viral mRNA VP23 (917 bp), and
actin mRNA (245 bp) as a control. As negative and positive PCR controls, water
and plasmid DNAs of full-length cDNA of VP23, actin, and K12 were used,
respectively.
TABLE 2. Surface phenotype of HHV-81 EBV1 and EBV1 LCLs
Cell line
Presence of a:
IgG IgM CD20 CD23 CD30 CD56 CD80
ABEH-1 (HHV-81 EBV1) 2 1 2 1 1 2 1
ABE-1 (HHV-82 EBV1) 1 1 2 1 1 2 1
GMEH-1 (HHV-81 EBV1) 2 1 2 1 1 2 1
GME-1 (HHV-82 EBV1) 1 1 2 1 1 2 1
BC-1 (HHV-81 EBV1) 2 1 2 1 2 2 1
BCBL-1 (HHV-81 EBV2) 2 1 2 1 1 2 2
a CD20, mature B cells and pre-B cells, not plasma cells (B1); CD23, mature
and/or activated B cells (low-affinity IgE receptor); CD30, activated B and T cells
(TNF receptor superfamily); CD56, interleukin-2-dependent T-cell clones, NK
cells (NCAM); CD80, activated B and T cells (B7-1 costimulatory molecule).
Expression of surface molecules was determined by immunofluorescence with
either FITC-conjugated polyclonal antibodies (IgG and IgM) or PE-conjugated
MAbs (CD20, CD23, CD30, CD56, and CD80).
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tween 1 in 104 and 1 in 106 (43). EBV present in isolated
PBMC can lead to the spontaneous outgrowth of immortal-
ized cells without the addition of EBV-containing superna-
tants; however, a minimal number of cells must be used (22,
23). In the experiments shown here, the number of cells used
was not sufficient for spontaneous outgrowth of EBV1 LCLs
(Table 1). In PBMC of none of the eight donors tested did
culture medium or Raji cell supernatant (Raji cells contain
EBV genomes but cannot produce infectious EBV) alone lead
to the outgrowth of immortalized B-cell lines. In contrast, su-
pernatants of BCBL-1 cells containing HHV-8 induced the
outgrowth of LCLs in PBMC of all four EBV1 donors but not
in PBMC of EBV2 donors.
The LCLs were persistently HHV-8 and EBV infected and
possessed the phenotype of activated B cells, similar to EBV1
LCLs. HHV-8 could also be transferred to PBMC from EBV2
donors, but only if BC-1 supernatants containing HHV-8 and
EBV were used. Thus, HHV-8 infects EBV1 B cells and favors
the outgrowth of immortalized LCLs containing both viruses.
Intriguingly, infection of PBMC with BC-1 supernatant did not
result in the outgrowth of EBV1 but, rather, resulted in the
outgrowth of HHV-81 EBV1 LCLs, which might indicate that
there is a selection for infection with both viruses. Moreover,
we cloned two HHV-81 EBV1 cell lines and tested eight
clones of one of them for the presence of HHV-8 and EBV by
PCR. All eight clones were HHV-81 EBV1, indicating that
none of the clones had lost either virus. Thus, there are several
lines of evidence suggesting that cells infected with both viruses
possess a growth advantage and that HHV-8 perhaps has an
intrinsic transforming potential. This is supported by the fact
that many BCBL cell lines are infected with both viruses. It is
formally possible that either of the two viruses is the primary
transforming agent in HHV-81 EBV1 LCLs whereas the other
virus provides an essential or nonessential (growth-promoting)
cofactor. If HHV-8 is a transforming virus for B lymphocytes,
FIG. 4. Detection of the HHV-8 protein kaposin in noninduced, lytic HHV-8 minor capsid protein VP23 and the lytic VCA of EBV in induced HHV-81 EBV1
ABEH-1 LCLs. EBV1 HHV-81 LCL ABEH-1 (a to f), BCBL-1 (g to l), and B95-8 (m to r) were either stained with MAb kap5C4 (b, h, and n), MAb Vp234G2 (d,
j, and p) or MAb directed to VCA of EBV (f, l, and r) after fixation with acetone. Cells stained with kap5C4 were noninduced, whereas cells stained with MAb VP234G2
or anti-VCA of EBV were induced with TPA and sodium butyrate. Bound antibodies were visualized with Cy3-conjugated goat anti-rat IgG or goat anti-mouse IgG
and examined under a Leica TNT confocal microscope.
TABLE 3. Serial passage of HHV-8 from HHV-81 EBV1
LCLs to PBMC of an EBV1 donor
Supernatanta LCLoutgrowthb
Expression ofc:
HHV-8 kaposin EBV VCA
Control 2 NDd ND
Raji 2 ND ND
ABEH-1 0.18 1 1
ABE-1 45 2 1
GMEH-1 1.4 1 1
GME-1 35 2 1
a Supernatants were prepared from ABEH-1 LCLs at passage 18, ABE-1
LCLs at passage 14, GMEH-1 LCLs at passage 23, and GME-1 LCLs at passage
14 as described in Materials and Methods.
b Expressed as 102 outgrowing LCLs at the highest dilution.
c Expression of HHV-8 kaposin and EBV VCA on outgrowing cells was
determined by immunofluorescence with the MAbs kap5C4 and 817, respec-
tively.
d ND, not done.
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it appears to depend on an EBV-derived cofactor, at least un-
der the conditions we used. An alternative explanation might
be a two-step transformation process, divided into an initiating
step and a maintaining step. In this case, the virus supplying
the initiating step should be lost at least in some cell lines, since
there is no selection for it. At the moment, however, we have
no evidence for this explanation. Interestingly, HHV-8 has no
homologs to EBNAs, LMPs, and EBERs; however, there are
several other candidates for transforming genes like v-IL6 (29,
33), cc-chemokines (21), G-protein-coupled receptor (3, 12),
v-cyclin (7, 8, 17), K1 (14), interferon regulatory factor (29, 31),
kaposin (32), v-FLIP (46), LANA (36), and v-bcl2 (9). Thus,
the mechanism by which HHV-8 supports transformation
might be different from that for EBV.
It is known that peripheral blood B lymphocytes can be
infected by HHV-8 in vivo in KS patients and healthy individ-
uals (1, 10, 25). At present, there is no evidence that these cells
are doubly infected by HHV-8 and EBV in vivo (4). In con-
trast, almost all of the PEL tumors are positive for both EBV
and HHV-8, implying that double infection could play a causal
role in this entity. In KS, only a minority of tumors are positive
for EBV. Thus, it is unlikely that both viruses in concert play a
role in tumorigenesis of KS. The primary target cell of HHV-8
infection is not yet known. This study provides some evidence
that B cells could be the primary reservoir and the place of
latency in HHV-8-infected individuals with and without KS. It
presents a model system of HHV-8 infection in vitro and might
give some clues about the role of B-cell infection in the patho-
genesis of HHV-8.
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